Surgery Partners (SGRY)
(Delayed Data from NSDQ)
$25.00 USD
-0.32 (-1.26%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $25.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SGRY 25.00 -0.32(-1.26%)
Will SGRY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SGRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGRY
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
DocGo Inc. (DCGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
SGRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Surgery Partners (SGRY) Q1 Earnings Expected to Decline
SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?
Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?
Other News for SGRY
Insider Sale: Chief Human Resources Officer Danielle Burkhalter Sells Shares of Surgery ...
Insider Sale: National Group President Bradley Owens Sells Shares of Surgery Partners Inc (SGRY)
Unveiling Surgery Partners (SGRY)'s Value: Is It Really Priced Right? A Comprehensive Guide
July 19th Options Now Available For Surgery Partners (SGRY)
Surgery Partners’ Growth Prospects Bolster Buy Rating